Clover Corporation Limited · ASX:CLV
Clover — Shareholder Meeting (November 2018)
17 slides from Clover's shareholder meeting presentation, Nov 23, 2018
Slide 1: Chairman's Report
CLOVER CORPORATION LIMITED ABN 85 003 622 866 CHAIRMAN’S REPORT For personal use only Clover Corporation Limited (Clover) reported a net profit after tax (NPAT) for the 12 months ended 31 July 2018 of $7.6m (2017: profit of $3.6m). Sales revenue in FY2018 was $63.0m (2017: $47.9m) an increase of 31.
Slide 2: Chairman's Report (continued)
Australia & New Zealand Strong demand in New Zealand has driven revenue, and Clover now has an additional New Zealand based executive to manage the customer relationships. The Australian and New Zealand markets have benefited from increased production facilities coming on line, with additional facto
Slide 3: Managing Director's Report 12 Months to 31 July 2018
For personal use only Managing Director’s Report 12 Months to 31 July 2018 23 November 2018
Slide 4: Vision and Mission Statement
For personal use only Vision and Mission Statement Vision To optimise the health and development of adults, infants and children. Mission To deliver science based bioactives which provide health benefits to adults, infants and children. 1
Slide 5: Full Year Performance Highlights
Full Year Performance Highlights For personal use only Total full year Revenue New products delivering $62.9m up 32% growth in new segments and countries on FY17 $47.9m driven by improved demand Inventory at $19.8m up $1.0m on FY17 full year Net Profit $7.6m up upon forward demand 109% on FY17 $
Slide 6: Full Year 2018 Results
For personal use only Full Year 2018 Results AUD million 4E Reported 4E Reported 32% year on year revenue 31 Jul 2018 31 Jul 2017 growth Revenue $62.9 $47.9 Australia/NZ key growth EBITDA $10.9 $6.1 region NPBT $10.6 $5.0 EBITDA $10.9m (PY $6.1m) Tax ($3.0) ($1.4) Fixed costs managed $8.3m N
Slide 7: Balance Sheet July 2018
Balance Sheet 31 July 2018 For personal use only AUD million Reported Reported Movement Cash balance 31 Jul 2018 31 July 2017 strong $7.9m Cash $7.9 $5.9 +$2.0m Trade receivables Trade $15.3 $12.1 +$3.2m up on FY17 Receivables reflects sales Inventories $19.8 $18.8 +$1.0m increase Total Current
Slide 8: Sales by Geography & Product
For personal use only Sales by Geography & Product Sales across key regions Encapsulated Tuna oil have grown during FY18 leads sales revenue with compared to FY17 encapsulated Algal oils and Australia/NZ continue to be other oils represented in major growth region for IF other products for the
Slide 9: Market Update
For personal use only Market Update Market changes Outcomes for Clover Slowing of CFDA registrations for Clover’s customers are cautious around International brands to sell in China inventory, as when CFDA licence awarded new cans are required New EU regulation requiring the mandatory EU inf
Slide 10: Overview of Melody Dairies investment
Overview of Melody Dairies For personal use only investment What is it? Melody Dairies is a separate company that will build and operate a nutritional spray dryer in Hamilton, New Zealand (NZ) Hamilton The Rationale Clover manufactures its nutritional powders on spray dryers The company has in
Slide 11: Overview of Melody Dairies investment cont.
Overview of Melody Dairies For personal use only investment cont. Solution and results Melody Dairies will be owned by four partners who will also have access to the dryer’s capacity equivalent to their share of the business The dryer has a capacity of 1.2 metric tonnes per hour providing Clover
Slide 12: An Update on Growth Platforms
For personal use only An Update on Growth Platforms Infant Market formula Development customers Product Development 6
Slide 13: Growth Platform: Market Development - Infant formula maintains growth
For personal use only Growth Platform Market Infant formula Development customer s Infant formula maintains growth Product Development Chinese consumer sentiment for Western brands is driving growth for customers Awarding of CFDA licenses to market and sell product in China has slowed, the CBEC
Slide 14: New products driving future growth
Market Infant formula For personal use only Development customers Growth Platform Product Development New products driving future growth Clover’s Hypoallergenic DHA product continues to win new customers and applications in speciality segments A highly concentrated DHA product which delivers 60%
Slide 15: New markets development
For personal use only Growth Platform Market Development Infant formula customers New markets development Product Development Clover has grown sales in USA, Europe, Asia and ANZ Australia & New Zealand has experienced significant growth servicing the Asian market with several new facilities star
Slide 16: 1HFY19 Outlook & Priorities
1HFY19 Outlook & Priorities For personal use only Growth in European markets driven by the requirement to increase DHA levels in infant formula Clover has entered into a contract to purchase a share of a spray drying facility in Hamilton, New Zealand Development of new products targeting sport
Slide 17: Disclaimer
For personal use only Disclaimer The release, publication or distribution of this presentation in certain jurisdictions may be restricted by law and therefore persons in such jurisdictions into which this presentation is released, published or distributed should inform themselves about and observe s